Literature DB >> 1434507

An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia.

H C Lou1, P B Toft, J Andresen, I Mikkelsen, B Olsen, F Güttler, S Wieslander, O Henriksen.   

Abstract

The study included 16 adolescents with optimally controlled hyperphenylalaninaemia (McKusick 26160), of whom six did not require treatment according to conventional criteria. All except the two patients with lowest median serum phenylalanine level throughout childhood (most values at 200-300 mumol/L) had white matter abnormalities detectable with magnetic resonance imaging. The lesions were particularly prominent in the watershed regions between the posterior and middle cerebral arteries. In most patients with moderate or severe hyperphenylalaninaemia frontal white matter lesions were present as well. Normal proton magnetic resonance spectra indicated that the lesions were stable. Occipital EEG abnormalities were frequent, and deficient performance on a pattern-recognition test was a characteristic neuropsychological finding. Serum phenylalanine levels at about 300 mumol/L or below throughout childhood and early adolescence may be required to avoid lesions. The present study demonstrates the limitations of even an optimally controlled dietary regimen in hyperphenylalaninaemia.

Entities:  

Mesh:

Year:  1992        PMID: 1434507     DOI: 10.1007/bf01800008

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

1.  Magnetic resonance imaging changes in early treated patients with phenylketonuria.

Authors:  A J Thompson; I Smith; B E Kendall; B D Youl; D Brenton
Journal:  Lancet       Date:  1991-05-18       Impact factor: 79.321

2.  Localized 1H in vivo NMR spectroscopy of small-volume elements in human brain at 1.5 T.

Authors:  W I Jung; W Grodd; O Lutz; D Petersen
Journal:  Magn Reson Med       Date:  1990-08       Impact factor: 4.668

3.  Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo.

Authors:  J Frahm; H Bruhn; M L Gyngell; K D Merboldt; W Hänicke; R Sauter
Journal:  Magn Reson Med       Date:  1989-01       Impact factor: 4.668

4.  Plasma amino acids in term neonates and infants with phenylketonuria before and after institution of the diet.

Authors:  A M Gerdes; J B Nielsen; H Lou; F Güttler
Journal:  Acta Paediatr Scand       Date:  1990-01

5.  Neuropathology of phenylketonuria.

Authors:  N Malamud
Journal:  J Neuropathol Exp Neurol       Date:  1966-04       Impact factor: 3.685

6.  Molecular basis of phenotypic heterogeneity in phenylketonuria.

Authors:  Y Okano; R C Eisensmith; F Güttler; U Lichter-Konecki; D S Konecki; F K Trefz; M Dasovich; T Wang; K Henriksen; H Lou
Journal:  N Engl J Med       Date:  1991-05-02       Impact factor: 91.245

7.  Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy.

Authors:  W Grodd; I Krägeloh-Mann; U Klose; R Sauter
Journal:  Radiology       Date:  1991-10       Impact factor: 11.105

Review 8.  Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood.

Authors:  F Güttler
Journal:  Acta Paediatr Scand Suppl       Date:  1980

9.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

10.  Long-term development of intelligence (IQ) and EEG in 34 children with phenylketonuria treated early.

Authors:  J Pietz; C Benninger; H Schmidt; D Scheffner; H Bickel
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

View more
  16 in total

1.  Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability.

Authors:  A C Ludolph; U Vetter; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

2.  Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials.

Authors:  A P Prince; M P McMurray; N R Buist
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

Review 3.  Late effects of phenylketonuria.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1995-12       Impact factor: 3.791

4.  Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: correlation with intelligence assessment.

Authors:  Steven Shinn-Forng Peng; Wen-Yih Isaac Tseng; Yin-Hsiu Chien; Wuh-Liang Hwu; Hon-Man Liu
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

5.  Mutation analysis in families with discordant phenotypes of phenylalanine hydroxylase deficiency. Inheritance and expression of the hyperphenylalaninaemias.

Authors:  P Guldberg; H L Levy; R Koch; C M Berlin; B Francois; K F Henriksen; F Güttler
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

7.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

8.  Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency.

Authors:  J Pietz; U K Meyding-Lamadé; H Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain.

Authors:  F A Hommes
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

10.  Brain magnetic resonance imaging in children with optimally controlled hyperphenylalaninaemia.

Authors:  P B Toft; H C Lou; I Krägeloh-Mann; J Andresen; F Güttler; P Guldberg; O Henriksen
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.